IL31 and dermatomyositis: In the context of dermatomyositis, lenabasum was also able to inhibit the expression of IL-31 in skin lesions, a cytokine upregulated in dermatomyositis patients suffering from pruritus, and to downregulate the release of IL-31 into the supernatants of PBMCs obtained from dermatomyositis patients and activated by the Toll-like receptor (TLR) 9 agonist CpG oligodeoxynucleotide [364].